210 related articles for article (PubMed ID: 22574970)
1. Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.
Xu XH; Huang LS; Yang J; Yu T; Tong JF; Yuan XG; Zhao XY
Leuk Lymphoma; 2013 Jan; 54(1):195-7. PubMed ID: 22574970
[No Abstract] [Full Text] [Related]
2. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
3. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
4. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
5. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
[No Abstract] [Full Text] [Related]
6. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
[No Abstract] [Full Text] [Related]
7. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
Baccarani M
Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
[No Abstract] [Full Text] [Related]
8. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
Akard LP; Cortes JE; Albitar M; Goldberg SL; Warsi G; Wetzler M; Ericson SG; Radich JP
Arch Pathol Lab Med; 2014 Sep; 138(9):1186-92. PubMed ID: 24308645
[TBL] [Abstract][Full Text] [Related]
9. Imatinib in chronic myeloid leukemia elderly patients.
Gugliotta G; Castagnetti F; Palandri F; Baccarani M; Rosti G
Aging (Albany NY); 2011 Dec; 3(12):1125-6. PubMed ID: 22203437
[No Abstract] [Full Text] [Related]
10. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
Sandoval C; Giamelli J; Jayabose S
J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
[No Abstract] [Full Text] [Related]
11. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
[No Abstract] [Full Text] [Related]
12. Bosutinib in the treatment of chronic myelogenous leukemia.
Cortes J
Clin Adv Hematol Oncol; 2012 Nov; 10(11):736-7. PubMed ID: 23271260
[No Abstract] [Full Text] [Related]
13. Improving the management of chronic myeloid leukaemia.
Neylon A; O'Brien S
Hosp Med; 2001 Sep; 62(9):553-5. PubMed ID: 11584615
[TBL] [Abstract][Full Text] [Related]
14. Kinase inhibitor therapy in CML: it's what's inside that counts.
Eide CA; Druker BJ; O'Hare T
Oncotarget; 2013 Sep; 4(9):1332-3. PubMed ID: 23934763
[No Abstract] [Full Text] [Related]
15. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
16. Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.
Yamazaki R; Aisa Y; Mori T; Iketani O; Ikeda Y; Okamoto S
Leuk Lymphoma; 2009 Apr; 50(4):670-2. PubMed ID: 19373671
[No Abstract] [Full Text] [Related]
17. [Mechanisms of resistance to BCR-ABL kinase inhibitors].
Diamond J; da Silva MG
Acta Med Port; 2013; 26(4):402-8. PubMed ID: 24016650
[TBL] [Abstract][Full Text] [Related]
18. Bone metabolism during long-term treatment with imatinib.
O'Sullivan S; Horne A; Wattie D; Porteous F; Gamble G; Browett P; Grey A
Leuk Lymphoma; 2013 Aug; 54(8):1783-5. PubMed ID: 23278638
[No Abstract] [Full Text] [Related]
19. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
Mesa RA; Steensma DP; Hoyer J; Ketterling RP
Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
[No Abstract] [Full Text] [Related]
20. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country.
Iqbal J; Ali Z; Khan AU; Aziz Z
Leuk Lymphoma; 2014 Sep; 55(9):2109-13. PubMed ID: 24237577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
